CD161

• Description :

  CD161 is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity[1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain

• Type :

  Reference compound

• Related Pathways :

  Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cd161.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC1=NC(C2=CC=NC3=CC=CC=C23)=C4C(NC5=C4C=C(OC)C(C6=C(C)ON=C6C)=C5)=N1

• Molecular Formula :

  C26H21N5O2

• Molecular Weight :

  435.48

• References & Citations :

  [1]Zhao Y, et al. Structure-Based Discovery of 4- (6-Methoxy-2-methyl-4- (quinolin-4-yl) -9H-pyrimido[4,5-b]indol-7-yl) -3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. J Med Chem. 2017 May 11;60 (9) :3887-3901.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1627716-22-6]